The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The sale is expected to close in the first quarter of 2022
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
The brand has added a range of exciting new products especially formulated for oily skin.
Recall does not include any metabolic deficiency nutrition formulas
With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Subscribe To Our Newsletter & Stay Updated
